Emmaus Life Sciences, Inc.announced today that it has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar Ministry of Public Health granting marketing authorization for the commercial distribution and sale of Endari in the country.
Read MoreEmmaus Life Sciences, Inc. today reported on its results of operations and financial condition as of and for the three and nine months ended September 30, 2022 and provided a business update
Read MoreEmmaus Life Sciences, Inc. today announced a collaboration with the Steve Harvey Morning Show cast member Kier (Junior) Spates to share Mr. Spate’s personal experience with the use of Endari, Emmaus’ prescription L-glutamine oral powder, to treat his sickle cell disease, or SCD.
Read MoreEmmaus Life Sciences, Inc. (OTCQX: EMMA), today reported financial results for the three and six months ended June 30, 2022 and provided a business update.
Read MoreLife Sciences Investor Forum: Company Executives Present Live June 23rd
Read More